{"gene":"MAP3K14","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":2008,"finding":"TRAF2 and TRAF3 form a ubiquitin ligase complex with cIAP1/cIAP2 that constitutively targets NIK (MAP3K14) for proteasomal degradation; receptor activation (CD40 or BAFF-R) triggers TRAF2-mediated K63-linked ubiquitination and activation of cIAP1/cIAP2, redirecting their E3 ligase activity to degrade TRAF3, thereby releasing NIK from the complex, stabilizing it, and enabling NF-κB2/p100 processing to p52.","method":"Co-immunoprecipitation, ubiquitination assays, TRAF3-deficient and TRAF2-deficient cell lines, mouse genetic models","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal biochemical assays plus genetic models, independently replicated across several labs","pmids":["18997792"],"is_preprint":false},{"year":2001,"finding":"NIK is selectively required for NF-κB transcriptional activation downstream of the lymphotoxin-β receptor (LTβR) but not downstream of TNF receptor or IL-1 receptor; NIK knockout mice show defects in lymphoid tissue development and antibody responses.","method":"Gene targeting/knockout mouse, NF-κB DNA binding assays, cytokine stimulation of NIK-/- cells, reporter gene assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined cellular and molecular phenotype, published in high-impact journal","pmids":["11251123"],"is_preprint":false},{"year":2012,"finding":"Crystal structure of the truncated human NIK kinase domain (with N-terminal extension) in complex with ATPγS at 2.5 Å reveals a constitutively active conformation that does not require phosphorylation; the N-terminal extension stabilizes helix αC in the active orientation, explaining NIK's intrinsic constitutive kinase activity and the gain-of-function of N-terminal deletion mutants.","method":"X-ray crystallography, kinase activity assays, mutational analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional validation","pmids":["22718757"],"is_preprint":false},{"year":2011,"finding":"The API2-MALT1 fusion oncoprotein proteolytically cleaves NIK at arginine 325; both API2 and MALT1 partners are required, and the resulting C-terminal NIK fragment retains kinase activity, is resistant to proteasomal degradation, and drives constitutive noncanonical NF-κB signaling, enhanced B-cell adhesion, and apoptosis resistance.","method":"Biochemical cleavage assays, mutagenesis (Arg325 site), co-expression experiments, NF-κB reporter assays, apoptosis/adhesion assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 1-2 — site-specific cleavage mapped with mutagenesis, multiple functional readouts","pmids":["21273489"],"is_preprint":false},{"year":2010,"finding":"Recruitment of TRAF3 and TRAF2 to the ligated LTβR competitively displaces NIK from the TRAF3-binding site (shown by charge-repulsion mutation ablating both LTβR and NIK binding to TRAF3); ligated LTβR also allosterically redirects the ubiquitin:NIK E3 ligase to polyubiquitinate and degrade TRAF3/TRAF2 via the RING domain of TRAF2, thereby halting NIK turnover and promoting NIK association with IKKα.","method":"Mutagenesis of TRAF3/TRAF2 receptor-binding domains, co-immunoprecipitation, ubiquitination assays, LTβR signaling reconstitution","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis combined with biochemical reconstitution defining a competitive displacement mechanism","pmids":["20348096"],"is_preprint":false},{"year":2014,"finding":"NIK contains an IAP-binding motif (IBM) at its amino terminus that interacts with the BIR2 domain of c-IAP1, providing substrate recognition for c-IAP1-mediated ubiquitylation and proteasomal degradation of NIK; IBM mutation stabilizes NIK and constitutively elevates p100-to-p52 processing and NF-κB target gene expression.","method":"Mutagenesis of the NIK IBM, co-immunoprecipitation with c-IAP1 BIR2 domain, ubiquitylation assays, NF-κB reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis of a defined motif combined with biochemical ubiquitylation assay and functional NF-κB readout","pmids":["25246529"],"is_preprint":false},{"year":2005,"finding":"NIK protein undergoes constitutive synthesis but rapid proteasomal degradation in resting B cells; BAFF and CD40L stabilize basally translated NIK post-translationally (without increasing mRNA or translation rate), and stabilized NIK is sufficient to trigger p100-to-p52 processing even in the presence of a protein synthesis inhibitor.","method":"Pulse-chase experiments, protein synthesis inhibitor treatment, immunoblot for NIK and p100/p52, stimulation with BAFF/CD40L vs. TNFα/PMA","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal biochemical methods defining the post-translational regulation mechanism","pmids":["16223731"],"is_preprint":false},{"year":2008,"finding":"NIK (MAP3K14) is localized to mitochondria in cancer cells and MEFs; NIK promotes mitochondrial fission and directional migration by recruiting Drp1 to mitochondria, forming a complex with Drp1, and regulating Drp1 phosphorylation (Ser-616) and dephosphorylation (Ser-637); this function is independent of IKKα/β and NF-κB.","method":"Subcellular fractionation, live-cell imaging, co-immunoprecipitation (NIK-Drp1 complex), Drp1 phosphorylation assays, IKK/NF-κB-null MEFs, invasion assays","journal":"Current biology","confidence":"High","confidence_rationale":"Tier 2 — direct localization with functional consequence, complex identified by Co-IP, IKK-independence established by genetic epistasis","pmids":["27889261"],"is_preprint":false},{"year":2015,"finding":"NIK (MAP4K4) binds and directly phosphorylates the Arp2 subunit of the Arp2/3 complex, increasing its nucleating activity; NIK kinase activity is necessary for EGF-stimulated Arp2 phosphorylation and plasma membrane protrusion in mammary carcinoma cells.","method":"In vitro kinase assay (recombinant NIK phosphorylating Arp2), co-immunoprecipitation, phospho-mimetic/phospho-dead Arp2 mutants, actin assembly assays, EGF stimulation of cells","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay with mutagenesis and functional actin assembly readout","pmids":["25601402"],"is_preprint":false},{"year":2001,"finding":"MAP4K4/NIK (the Ste20-related kinase, not the NF-κB-inducing kinase) is essential for mesodermal and endodermal cell migration during gastrulation; NIK-null mouse embryos die at E9.5-10.5 with failure of presomitic mesodermal cells to migrate from the primitive streak; chimeric analysis reveals both cell-nonautonomous (migration stimulation) and cell-autonomous (dermomyotome differentiation) functions.","method":"Homologous recombination knockout, embryo phenotype analysis, chimeric mouse analysis","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined developmental phenotype and chimeric rescue dissecting cell-autonomous vs non-autonomous roles","pmids":["11290295"],"is_preprint":false},{"year":2008,"finding":"TRAF3 depletion leads to accumulation of NIK, which then activates both canonical (p50-dependent) and noncanonical (p52-dependent) NF-κB pathways; deregulated canonical NF-κB activation in TRAF3-deficient cells is dependent on NIK accumulation.","method":"TRAF3-deficient cell lines, NIK knockdown/overexpression, NF-κB reporter assays, EMSA, immunoblot for p100/p52 processing","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis (TRAF3 KO rescued by NIK depletion) with multiple NF-κB readouts","pmids":["18292232"],"is_preprint":false},{"year":2008,"finding":"NIK is required for osteoclast differentiation; NIK deficiency blocks both alternative and classical NF-κB due to cytoplasmic p100 retention; p100 deletion or RelB overexpression (but not p65) rescues osteoclastogenesis in NIK-/- precursors; RelB-/- mice show impaired osteoclast formation and reduced tumor-induced osteolysis.","method":"NIK-/- and RelB-/- mouse osteoclast cultures, retroviral overexpression of RelB/p65, in vivo serum transfer/tumor models, bone histomorphometry","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with specific rescue experiments and in vivo validation","pmids":["18322009"],"is_preprint":false},{"year":2012,"finding":"NIK promotes glucagon-stimulated hepatic glucose production in obesity by increasing cAMP response element-binding protein (CREB) stability; hepatic NIK is abnormally activated in obese mice; liver-specific inhibition of NIK reduces glucagon responses and HGP, while hepatocyte-specific NIK overexpression increases them.","method":"Map3k14 systemic knockout, liver-specific NIK deletion, hepatocyte-specific NIK transgene, primary hepatocyte glucose production assays, CREB stability assays","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic models (KO, conditional KO, transgene) with defined molecular mechanism (CREB stability)","pmids":["22581287"],"is_preprint":false},{"year":2009,"finding":"NIK is required for Th17 cell differentiation; NIK-deficient naive CD4+ T cells are defective in Th17 commitment but not other lineages; NIK mediates synergistic STAT3 activation by TCR and IL-6 receptor signals, and its loss attenuates STAT3 phosphorylation and STAT3 target gene induction needed for Th17 commitment; NIK-/- mice are resistant to EAE.","method":"NIK-/- mouse T-cell differentiation assays, Rag2-/- reconstitution with NIK-/- T cells, STAT3 phosphorylation assays, EAE model","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — clean KO with T-cell-intrinsic reconstitution proof and molecular STAT3 mechanism","pmids":["19411637"],"is_preprint":false},{"year":2014,"finding":"Biallelic loss-of-function mutations in MAP3K14 (NIK) cause primary immunodeficiency in humans; mutant NIK loses kinase activity (confirmed by functional assays), leading to defective canonical and noncanonical NF-κB activation, B-cell lymphopenia, impaired ICOSL expression, perturbed follicular helper and memory T cells, and defective NK-cell immunological synapse formation.","method":"Patient genetics, NIK kinase activity assays, NF-κB signaling assays, flow cytometry of lymphocyte subsets, NK-cell immunological synapse imaging","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — human loss-of-function with in vitro kinase assay confirmation and multiple immune functional readouts","pmids":["25406581"],"is_preprint":false},{"year":2018,"finding":"NIK interacts with the innate DNA-sensing adaptor STING independently of alternative NF-κB signaling components; NIK autophosphorylation and oligomerization are required to activate STING-dependent IFN induction; NIK-deficient mice are more susceptible to DNA virus infection; TRAF3, a positive regulator of RNA-pathway IFN, inhibits the DNA pathway by limiting NIK availability.","method":"NIK-/- mouse infection models, co-immunoprecipitation of NIK-STING, autophosphorylation assays, NIK oligomerization assays, IFN reporter assays, epistasis with alternative NF-κB components","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, in vitro kinase assays, in vivo infection model, epistasis experiments","pmids":["30018345"],"is_preprint":false},{"year":2007,"finding":"NIK confers IKKα the ability to activate IRF3/7 for IFN production; NIK phosphorylates IKKα at Ser-176 and Ser-180, but these two phosphorylations have differential effects: IKKα(S176E) constitutively activates IRF3/7 while IKKα(S180E) loses this ability, revealing that NIK differentially regulates NF-κB versus IRF3/7 activation through IKKα.","method":"Phosphomimetic IKKα mutagenesis (S176E, S180E), IRF3/7 reporter assays, TLR7/9 stimulation, kinase assays","journal":"Molecular immunology","confidence":"High","confidence_rationale":"Tier 1 — site-specific mutagenesis with differential functional outcomes establishes mechanism","pmids":["18068231"],"is_preprint":false},{"year":2005,"finding":"NIK physically interacts with IKKβ (but not IKKα or IKKγ) and with a novel brain-enriched protein NIBP (identified by yeast two-hybrid screen); NIBP overexpression potentiates TNFα-induced NF-κB activation through increased IKK complex phosphorylation and downstream IκBα/p65 phosphorylation, while NIBP knockdown reduces NF-κB activation.","method":"Yeast two-hybrid screen, co-immunoprecipitation, overexpression/siRNA knockdown in PC12 cells, NF-κB reporter assays, phosphorylation assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 3 — yeast two-hybrid plus single Co-IP; functional follow-up supports interaction","pmids":["15951441"],"is_preprint":false},{"year":2003,"finding":"NIK is a component of EGF/heregulin receptor signaling complexes; NIK interacts with Grb7 (via Grb7's GM domain), Grb10, and Grb14, and can be simultaneously recruited with Grb7 into EGFR, ErbB2, ErbB3, and ErbB4 complexes; NIK potentiates EGF/heregulin-induced NF-κB activation, and EGF activates NF-κB in wild-type but not NIK-/- fibroblasts.","method":"Antibody array screen for NIK-associated proteins, co-immunoprecipitation, domain mapping (Grb7 GM domain), NF-κB reporter assays in NIK-/- MEFs","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2-3 — antibody array + Co-IP + NIK-/- genetic test; solid but single lab","pmids":["12853971"],"is_preprint":false},{"year":2003,"finding":"Cytokine (IL-1/TNFα)-induced suppression of PPAR-γ adipogenic function is mediated through the TAK1/TAB1/NIK cascade activating NF-κB; NF-κB blocks PPAR-γ DNA binding by forming a complex with PPAR-γ and its AF-1-specific co-activator PGC-2.","method":"Dominant-negative kinase constructs, NF-κB reporter assays, co-immunoprecipitation of NF-κB/PPAR-γ/PGC-2 complex, PPAR-γ DNA binding assays, adipogenesis assays","journal":"Nature cell biology","confidence":"Medium","confidence_rationale":"Tier 2 — dominant-negative epistasis combined with complex Co-IP, but TAK1/TAB1 aspects complicate direct NIK attribution","pmids":["12598905"],"is_preprint":false},{"year":2015,"finding":"NIK promotes TNFR1-mediated RIP1-dependent apoptosis independently of alternative NF-κB (p100-to-p52 processing); NIK stabilization (via Fn14 or LTβR) is required for TNFα-induced cIAP1/2 depletion to trigger RIP1 phosphorylation and RIP1/FADD/caspase-8 complex assembly; in vitro kinase assays show RIP1 is a direct NIK substrate.","method":"In vitro kinase assay (NIK phosphorylating RIP1), genetic models (NIK-/- and p100-/- mice), thymus involution and liver damage in vivo models, immunoprecipitation of RIP1/FADD/caspase-8 complex","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro kinase assay identifying RIP1 as NIK substrate, with in vivo genetic validation","pmids":["26045047"],"is_preprint":false},{"year":2003,"finding":"NIK mediates NF-κB activation downstream of caspase-8 and caspase-10 prodomain isoforms (PDCasp8/10); GST pulldown shows NIK (and RIP) directly bind PDCasp8/10; dominant-negative IKKα or kinase-dead RIP blocks PDCasp8/10-mediated NF-κB activation; siRNA knockdown shows IKKα (not IKKβ) is the relevant downstream kinase.","method":"GST pulldown, dominant-negative mutants, siRNA knockdown, NF-κB reporter assays","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 3 — GST pulldown with functional dominant-negative and siRNA validation; single lab","pmids":["12884866"],"is_preprint":false},{"year":2018,"finding":"NIK promotes liver inflammation and fibrosis through a hepatocyte NIK-liver immune cell (macrophage) axis; hepatocyte NIK overexpression stimulates release of chemokines/cytokines that activate macrophages, which in turn secrete proapoptotic factors inducing hepatocyte apoptosis; depletion of Kupffer cells/macrophages reverses NIK-induced liver destruction.","method":"Hepatocyte-specific NIK transgene, primary hepatocyte conditioned medium experiments, macrophage activation assays, Kupffer cell depletion, liver histology/fibrosis assays","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 2 — transgenic model with mechanistic dissection (macrophage depletion rescue), multiple orthogonal readouts","pmids":["25088600"],"is_preprint":false},{"year":2018,"finding":"NIK (MAP3K14) and its substrate IKKα suppress the mitogenic JAK2/STAT3 pathway to restrain hepatocyte proliferation and liver regeneration; hepatocyte-specific deletion of Map3k14 or Chuk (IKKα) substantially accelerates hepatocyte proliferation after partial hepatectomy, even under liver disease conditions (hepatotoxin or high-fat diet).","method":"Hepatocyte-specific Map3k14 and Chuk knockout mice, partial hepatectomy, STAT3/JAK2 phosphorylation assays, cell cycle analysis, liver disease models","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 — conditional KO of both NIK and its substrate IKKα with defined JAK2/STAT3 mechanism and multiple disease models","pmids":["30070632"],"is_preprint":false},{"year":2011,"finding":"NIK stabilization in osteoclast precursors (via deletion of TRAF3-binding domain) constitutively activates alternative NF-κB and enhances both osteoclast differentiation speed and resorptive function, causing high-turnover osteoporosis and exaggerated inflammatory osteolysis in vivo.","method":"OC-lineage transgenic mice expressing TRAF3-binding-deficient NIK (NT3), in vitro osteoclastogenesis assays, bone resorption/actin ring measurements, serum transfer arthritis model","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — transgenic gain-of-function with defined NF-κB mechanism and multiple in vivo/in vitro readouts","pmids":["21151480"],"is_preprint":false},{"year":2023,"finding":"EDA-A2 ligand activates EDA2R receptor signaling that requires NIK activity to promote skeletal muscle atrophy; EDA-A2 stimulation induces noncanonical NF-κB pathway activation and upregulates Atrogin1/MuRF1; muscle-specific NIK deletion protects tumour-bearing mice from cancer cachexia-associated muscle wasting; oncostatin M (OSM) upregulates muscle EDA2R expression upstream of NIK.","method":"Primary myotube EDA-A2 stimulation assays, muscle-specific NIK knockout mice, EDA2R knockout mice, tumour-bearing mouse cachexia model, NIK kinase inhibitor treatment, OSMR muscle-specific KO","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — multiple conditional KO models with in vivo functional validation of EDA2R-NIK axis","pmids":["37165186"],"is_preprint":false},{"year":2022,"finding":"Biliary NIK promotes ductular reaction independently of its canonical substrate IKKα; cholangiocyte-specific NIK deletion (but not IKKα deletion) blunts cholestasis-induced ductular reaction, liver injury, inflammation and fibrosis; NIK directly increases cholangiocyte proliferation, suppresses their death, and stimulates secretion of cholangiokines that activate macrophages and hepatic stellate cells.","method":"Cholangiocyte-specific NIK KO, cholangiocyte-specific IKKα KO, BDL/DDC/ANIT cholestasis models, NIK inhibitor treatment, cholangiocyte proliferation/apoptosis assays, cholangiokine secretion assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — genetic dissection of NIK vs IKKα with multiple models and mechanistic cell-type-specific readouts","pmids":["36042192"],"is_preprint":false},{"year":2015,"finding":"NIK is required in dendritic cells for CD40-dependent cross-priming of CD8+ T cells; DC-specific NIK deletion impairs antigen cross-presentation to CD8+ T cells and IL-12p40 secretion by splenic CD8+ DCs, without affecting antigen presentation to CD4+ T cells.","method":"CD11c-Cre NIK conditional knockout mice, vaccination/cross-priming assays, in vitro cross-presentation assays, cytokine ELISA","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with specific cell-type functional readouts distinguishing CD8+ vs CD4+ presentation","pmids":["26561586"],"is_preprint":false},{"year":2018,"finding":"DC-specific NIK activates noncanonical NF-κB to induce IL-23 expression in intestinal DCs, which maintains TH17 cells and type 3 ILCs; these produce IL-17 that drives pIgR expression on intestinal epithelial cells, enabling IgA secretion and microbiota homeostasis; DC-specific NIK deletion renders mice sensitive to Citrobacter rodentium and ameliorates colitis.","method":"DC-specific NIK knockout mice, intestinal IgA measurements, TH17/ILC3 quantification, IL-23/IL-17/pIgR expression assays, infection and colitis models","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with mechanistic pathway dissection (NIK→IL-23→IL-17→pIgR) and in vivo infection/disease models","pmids":["30250187"],"is_preprint":false},{"year":2018,"finding":"NIK in lymphatic endothelial cells (LECs) regulates B-cell homing to lymph nodes by mediating expression of CXCL13 (exclusively in LECs, not blood endothelial cells) and CCL19; LEC-conditional NIK deletion severely reduces B-cell frequency in LNs without affecting LN integrity or splenic B cells.","method":"LEC-specific NIK conditional KO mice, B-cell adoptive transfer assays, chemokine ELISA/qPCR, flow cytometry of LN/spleen B-cell subsets","journal":"Cellular & molecular immunology","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with B-cell adoptive transfer establishing LEC-intrinsic NIK→CXCL13 mechanism","pmids":["29503445"],"is_preprint":false},{"year":2011,"finding":"NIK (MAP3K14) mediates cigarette smoke (CS)- and TNFα-induced histone H3K9 acetylation at pro-inflammatory gene promoters via phosphorylation of IKKα; NIK accumulates in the nuclear compartment and is recruited to promoters of pro-inflammatory genes; NIK knockdown attenuates CS/TNFα-induced histone acetylation; the canonical IKKβ/NF-κB pathway does not mediate CS-induced histone acetylation.","method":"NIK siRNA knockdown, chromatin immunoprecipitation (ChIP) for NIK and acetylated H3K9, in vivo CS exposure mouse model, immunoblot for nuclear NIK, IKKα/β phosphorylation","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2-3 — ChIP showing NIK at promoters plus siRNA knockdown; single lab with mechanistic detail","pmids":["21887257"],"is_preprint":false},{"year":2022,"finding":"NEK2 phosphorylates NIK (MAP3K14), increasing NIK activity and stability, thereby activating noncanonical NF-κB signaling to promote GBM malignancy; NEK2 knockdown reduces NIK-dependent NF-κB activity and tumor progression.","method":"Co-immunoprecipitation, kinase assays showing NEK2 phosphorylates NIK, siRNA knockdown, NF-κB reporter assays, in vivo xenograft transplantation","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2-3 — kinase assay plus Co-IP identifies NEK2 as a writer for NIK; single lab","pmids":["35031599"],"is_preprint":false}],"current_model":"MAP3K14/NIK is a constitutively active serine/threonine kinase that is kept at very low levels in resting cells through continuous proteasomal degradation mediated by a TRAF3-TRAF2-cIAP1/2 E3 ubiquitin ligase complex (which recognizes NIK via an amino-terminal IBM motif); receptor activation (LTβR, CD40, BAFF-R, EDA2R) triggers competitive displacement of NIK from TRAF3 and TRAF2-dependent K63-ubiquitination and degradation of TRAF3, stabilizing NIK to phosphorylate IKKα and drive NF-κB2/p100 processing to p52/RelB (noncanonical pathway), while also regulating canonical NF-κB, IRF3/7-dependent IFN production via STING, STAT3-dependent Th17 differentiation, JAK2/STAT3-mediated hepatocyte proliferation, RIP1-dependent apoptosis, and IKK-independent mitochondrial fission via Drp1 and actin dynamics via Arp2/3 complex phosphorylation."},"narrative":{"teleology":[{"year":2001,"claim":"Defining the physiological requirement for NIK: whereas overexpression studies had implicated NIK broadly in NF-κB signaling, knockout mice revealed a selective requirement for LTβR-dependent NF-κB activation and lymphoid organogenesis, narrowing NIK's role to specific receptor pathways.","evidence":"NIK knockout mice analyzed for NF-κB activation by multiple stimuli and lymphoid organ development","pmids":["11251123"],"confidence":"High","gaps":["Molecular mechanism of selective LTβR dependence was unknown","Whether NIK had NF-κB-independent functions was not addressed","Downstream substrate identity unresolved"]},{"year":2005,"claim":"Establishing post-translational stabilization as the activation mechanism: pulse-chase experiments showed NIK protein is constitutively synthesized and rapidly degraded in resting B cells, and BAFF/CD40L signals stabilize NIK protein without increasing transcription, explaining how receptor signals activate NIK.","evidence":"Pulse-chase, protein synthesis inhibitor experiments in B cells stimulated with BAFF or CD40L","pmids":["16223731"],"confidence":"High","gaps":["The E3 ligase responsible for constitutive degradation was not identified","Whether stabilization mechanism applied to non-B cell types was untested"]},{"year":2008,"claim":"Identification of the degradation machinery: the TRAF3–TRAF2–cIAP1/2 complex was shown to constitutively ubiquitinate NIK for proteasomal destruction, and receptor engagement redirected cIAP activity to degrade TRAF3, releasing NIK; this explained both constitutive silencing and signal-induced activation of the noncanonical pathway.","evidence":"Co-IP, ubiquitination assays, TRAF3/TRAF2-deficient cells, and mouse genetic models across multiple labs","pmids":["18997792","18292232"],"confidence":"High","gaps":["How TRAF3 physically contacts NIK was not mapped","Whether TRAF3 loss activates canonical NF-κB through NIK needed further dissection"]},{"year":2010,"claim":"Resolving the competitive displacement mechanism: mutagenesis showed that LTβR and NIK bind the same TRAF3 interface, so receptor ligation physically displaces NIK while recruiting TRAF3/TRAF2 for degradation, providing the switch logic for NIK stabilization.","evidence":"Charge-repulsion mutagenesis of TRAF3 receptor-binding site, Co-IP, LTβR signaling reconstitution","pmids":["20348096"],"confidence":"High","gaps":["Stoichiometric and kinetic parameters of the switch unknown","Whether all NIK-activating receptors use the same displacement mechanism was untested"]},{"year":2012,"claim":"Structural basis for constitutive kinase activity: the crystal structure of the NIK kinase domain revealed a constitutively active conformation stabilized by an N-terminal extension locking helix αC, explaining why NIK does not require activation-loop phosphorylation and why N-terminal truncations are gain-of-function.","evidence":"X-ray crystallography at 2.5 Å with ATPγS, kinase activity assays, and mutational analysis","pmids":["22718757"],"confidence":"High","gaps":["Full-length NIK structure including regulatory domains unavailable","How the IBM and TRAF3-binding regions interact with the kinase domain structurally unknown"]},{"year":2014,"claim":"Mapping the cIAP1 recognition motif on NIK: an N-terminal IAP-binding motif (IBM) on NIK was shown to directly engage cIAP1's BIR2 domain, providing the substrate-recognition mechanism for constitutive ubiquitination; IBM mutation stabilized NIK and constitutively activated p100 processing.","evidence":"IBM mutagenesis, Co-IP with cIAP1 BIR2, ubiquitylation assays, NF-κB reporter assays","pmids":["25246529"],"confidence":"High","gaps":["Whether receptor signals modify the IBM-BIR2 interface is unknown","Structural details of IBM-BIR2 interaction not resolved"]},{"year":2007,"claim":"Expanding NIK function beyond NF-κB: NIK-mediated phosphorylation of IKKα at Ser-176 versus Ser-180 was shown to differentially activate IRF3/7-dependent interferon production versus NF-κB, establishing NIK as a bifunctional signaling node.","evidence":"Phosphomimetic IKKα mutagenesis (S176E, S180E), IRF3/7 reporter assays, TLR stimulation","pmids":["18068231"],"confidence":"High","gaps":["Structural basis for differential substrate presentation unknown","In vivo validation of the dual-phosphorylation model not provided"]},{"year":2009,"claim":"NIK links adaptive immunity to T-helper cell fate: NIK-deficient T cells were selectively impaired in Th17 differentiation through defective STAT3 activation downstream of synergistic TCR and IL-6R signals, and NIK-null mice were resistant to EAE.","evidence":"NIK-/- T-cell differentiation, Rag2-/- reconstitution, STAT3 phosphorylation assays, EAE model","pmids":["19411637"],"confidence":"High","gaps":["Direct substrate linking NIK to STAT3 phosphorylation not identified","Whether NIK acts through IKKα or independently in this context was unresolved"]},{"year":2011,"claim":"Oncogenic hijacking of NIK: the API2-MALT1 fusion oncoprotein was shown to proteolytically cleave NIK at Arg325, generating a degradation-resistant C-terminal kinase fragment that drives constitutive noncanonical NF-κB, linking NIK stabilization to MALT lymphoma pathogenesis.","evidence":"Biochemical cleavage assays, Arg325 mutagenesis, NF-κB reporter and adhesion/apoptosis assays","pmids":["21273489"],"confidence":"High","gaps":["Whether therapeutic targeting of the cleavage product is feasible unknown","Frequency and contribution of this mechanism across MALT lymphoma subtypes unclear"]},{"year":2011,"claim":"NIK in bone biology: NIK stabilization in osteoclast precursors accelerated osteoclastogenesis and bone resorption via constitutive alternative NF-κB, while NIK deficiency blocked osteoclast differentiation through cytoplasmic p100 retention, establishing NIK as a critical regulator of bone homeostasis.","evidence":"Transgenic gain-of-function (TRAF3-binding-deficient NIK), NIK-/- osteoclast cultures, bone resorption assays, arthritis models","pmids":["21151480","18322009"],"confidence":"High","gaps":["NIK's role in osteoblasts not examined","Whether therapeutic NIK inhibition could treat osteoporosis without immunosuppression unknown"]},{"year":2012,"claim":"Metabolic function of NIK: hepatic NIK was shown to promote glucagon-stimulated glucose production by stabilizing CREB; NIK was abnormally activated in obese mouse livers, linking NIK to metabolic disease.","evidence":"Liver-specific NIK KO, hepatocyte-specific transgene, primary hepatocyte glucose production, CREB stability assays","pmids":["22581287"],"confidence":"High","gaps":["How NIK stabilizes CREB mechanistically (direct phosphorylation vs indirect) not resolved","Human relevance of hepatic NIK elevation in obesity not established"]},{"year":2014,"claim":"Human disease causation: biallelic loss-of-function MAP3K14 mutations were identified as a cause of primary immunodeficiency, with abolished kinase activity leading to defective NF-κB activation, B-cell lymphopenia, and impaired NK-cell function, confirming the mouse knockout phenotype in humans.","evidence":"Patient genetics, in vitro kinase assays, lymphocyte subset flow cytometry, NK synapse imaging","pmids":["25406581"],"confidence":"High","gaps":["Genotype-phenotype spectrum in additional patients not established","Whether partial loss-of-function alleles cause milder phenotypes unknown"]},{"year":2015,"claim":"NF-κB-independent apoptotic function: NIK was shown to directly phosphorylate RIP1 and promote RIP1/FADD/caspase-8 complex assembly for TNFR1-mediated apoptosis, a function independent of p100 processing, revealing that NIK integrates cell death and survival signals.","evidence":"In vitro kinase assay (NIK phosphorylating RIP1), NIK-/- and p100-/- mice, in vivo thymus/liver damage models","pmids":["26045047"],"confidence":"High","gaps":["RIP1 phosphorylation site(s) not identified","How cells balance NIK's pro-survival NF-κB and pro-death RIP1 functions unclear"]},{"year":2016,"claim":"NF-κB-independent mitochondrial function: NIK was found to localize to mitochondria and promote fission by recruiting and regulating Drp1 phosphorylation (Ser-616/Ser-637), independently of IKKα/β, linking NIK to organelle dynamics and cell migration.","evidence":"Subcellular fractionation, live-cell imaging, Co-IP of NIK-Drp1, IKK-null MEFs, invasion assays","pmids":["27889261"],"confidence":"High","gaps":["How NIK is targeted to mitochondria unknown","Whether mitochondrial NIK pool is regulated by the TRAF3 degradation machinery unclear"]},{"year":2018,"claim":"Innate DNA sensing: NIK was shown to interact with STING independently of alternative NF-κB components; NIK autophosphorylation and oligomerization activate STING-dependent IFN, and NIK-deficient mice are more susceptible to DNA viruses, establishing NIK as a node linking innate DNA sensing to interferon production.","evidence":"Reciprocal Co-IP of NIK-STING, autophosphorylation/oligomerization assays, IFN reporters, in vivo DNA virus infection","pmids":["30018345"],"confidence":"High","gaps":["Whether NIK directly phosphorylates STING or another intermediate unknown","Relationship between NIK-STING and NIK-IKKα-IRF3 pathways not clarified"]},{"year":2018,"claim":"Hepatocyte proliferation control: conditional deletion of NIK or IKKα in hepatocytes accelerated liver regeneration after partial hepatectomy by derepressing JAK2/STAT3, positioning NIK-IKKα as a brake on hepatocyte proliferation.","evidence":"Hepatocyte-specific Map3k14 and Chuk KO mice, partial hepatectomy, JAK2/STAT3 phosphorylation, disease models","pmids":["30070632"],"confidence":"High","gaps":["Mechanism by which NIK-IKKα suppresses JAK2/STAT3 not identified","Whether this pathway operates in non-hepatocyte epithelial cells untested"]},{"year":2018,"claim":"Cell-type-specific immune roles: DC-specific NIK was shown to drive IL-23 production for intestinal Th17/ILC3 maintenance and IgA homeostasis, while LEC-specific NIK controlled CXCL13-dependent B-cell homing to lymph nodes, demonstrating that NIK acts through distinct effector programs in different stromal and immune cell types.","evidence":"DC-specific and LEC-specific NIK conditional KO mice, infection/colitis models, B-cell adoptive transfer, chemokine assays","pmids":["30250187","29503445"],"confidence":"High","gaps":["Whether NIK-dependent transcriptional programs differ across DC subsets not fully resolved","Upstream receptor activating NIK in LECs not identified"]},{"year":2022,"claim":"IKKα-independent biliary function: cholangiocyte-specific NIK deletion (but not IKKα deletion) blunted ductular reaction, fibrosis, and inflammation during cholestasis, demonstrating an IKKα-independent NIK effector pathway in biliary epithelial cells.","evidence":"Cholangiocyte-specific NIK KO vs IKKα KO, BDL/DDC/ANIT cholestasis models, proliferation/apoptosis/cholangiokine assays","pmids":["36042192"],"confidence":"High","gaps":["The IKKα-independent substrate mediating ductular reaction not identified","Whether this pathway contributes to cholangiocarcinoma unknown"]},{"year":2023,"claim":"Muscle atrophy via EDA2R-NIK axis: EDA-A2/EDA2R signaling was shown to activate NIK-dependent noncanonical NF-κB in skeletal muscle, upregulating atrophy genes; muscle-specific NIK deletion protected against cancer cachexia, identifying a new receptor-kinase axis in muscle wasting.","evidence":"Primary myotube assays, muscle-specific NIK KO, EDA2R KO, tumor-bearing cachexia models, NIK inhibitor treatment","pmids":["37165186"],"confidence":"High","gaps":["Whether NIK inhibitors can treat cachexia without immunosuppression unknown","Direct NIK substrates in skeletal muscle not characterized"]},{"year":null,"claim":"Major unresolved questions include the full-length structure of NIK with its regulatory domains, the mechanism by which NIK is targeted to mitochondria, the identity of IKKα-independent substrates in cholangiocytes, and how cells integrate NIK's pro-survival (NF-κB), pro-death (RIP1), and metabolic (CREB, JAK2/STAT3) outputs.","evidence":"","pmids":[],"confidence":"Low","gaps":["Full-length NIK structure unavailable","Mitochondrial targeting mechanism unknown","IKKα-independent downstream effectors in non-immune cells unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[2,7,8,16,20,31]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[2]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[7]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[30]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,6]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,4,5,6,10,14,16,25]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,11,13,14,27,28,29]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[20]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1,11,24]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[12]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[7]}],"complexes":["TRAF3-TRAF2-cIAP1/2 degradation complex (substrate)"],"partners":["TRAF3","TRAF2","BIRC2","CHUK","STING1","DNM1L","RIPK1","NEK2"],"other_free_text":[]},"mechanistic_narrative":"MAP3K14 (NF-κB-inducing kinase, NIK) is a constitutively active serine/threonine kinase that serves as the central signaling hub for the noncanonical NF-κB pathway while also regulating canonical NF-κB, interferon responses, apoptosis, mitochondrial dynamics, and metabolic homeostasis. In resting cells, NIK is continuously synthesized but rapidly degraded via a TRAF3–TRAF2–cIAP1/2 ubiquitin ligase complex that recognizes an N-terminal IAP-binding motif on NIK; receptor ligation (LTβR, CD40, BAFF-R, EDA2R) competitively displaces NIK from TRAF3 and redirects cIAP-mediated ubiquitination to degrade TRAF3, thereby stabilizing NIK to phosphorylate IKKα and drive p100-to-p52/RelB processing [PMID:18997792, PMID:20348096, PMID:25246529, PMID:16223731]. Beyond NF-κB, stabilized NIK activates STING-dependent type I interferon production, phosphorylates RIP1 to promote TNFR1-mediated apoptosis, suppresses hepatocyte proliferation through JAK2/STAT3, promotes Th17 differentiation via STAT3, and drives IKK-independent mitochondrial fission by recruiting and phosphorylating Drp1 [PMID:30018345, PMID:26045047, PMID:30070632, PMID:19411637, PMID:27889261]. Biallelic loss-of-function mutations in MAP3K14 cause a human primary immunodeficiency characterized by B-cell lymphopenia, impaired NF-κB activation, and defective NK-cell synapse formation [PMID:25406581]."},"prefetch_data":{"uniprot":{"accession":"Q99558","full_name":"Mitogen-activated protein kinase kinase kinase 14","aliases":["NF-kappa-beta-inducing kinase","HsNIK","Serine/threonine-protein kinase NIK"],"length_aa":947,"mass_kda":104.0,"function":"Lymphotoxin beta-activated kinase which seems to be exclusively involved in the activation of NF-kappa-B and its transcriptional activity. Phosphorylates CHUK/IKKA, thereby promoting proteolytic processing of NFKB2/P100, which leads to NF-kappa-B activation via the non-canonical pathway (PubMed:25406581, PubMed:29230214). Has an essential role in the non-canonical NF-kappa-B signaling that regulates genes encoding molecules involved in B-cell survival, lymphoid organogenesis, and immune response (PubMed:25406581). Could act in a receptor-selective manner","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q99558/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MAP3K14","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":74,"dependency_fraction":0.05405405405405406},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MAP3K14","total_profiled":1310},"omim":[{"mim_id":"620449","title":"IMMUNODEFICIENCY 112; IMD112","url":"https://www.omim.org/entry/620449"},{"mim_id":"619289","title":"ZINC FINGER PROTEIN 91, ATYPICAL E3 UBIQUITIN LIGASE; ZFP91","url":"https://www.omim.org/entry/619289"},{"mim_id":"618428","title":"POPOV-CHANG SYNDROME; POPCHAS","url":"https://www.omim.org/entry/618428"},{"mim_id":"615577","title":"IMMUNODEFICIENCY, COMMON VARIABLE, 10; CVID10","url":"https://www.omim.org/entry/615577"},{"mim_id":"614061","title":"OLFACTOMEDIN 4; OLFM4","url":"https://www.omim.org/entry/614061"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Vesicles","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Nucleoli fibrillar center","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MAP3K14"},"hgnc":{"alias_symbol":["NIK","HSNIK","FTDCR1B","HS"],"prev_symbol":[]},"alphafold":{"accession":"Q99558","domains":[{"cath_id":"3.30.200.20","chopping":"334-367_374-470","consensus_level":"high","plddt":91.5405,"start":334,"end":470},{"cath_id":"1.10.510.10","chopping":"478-659","consensus_level":"high","plddt":91.8634,"start":478,"end":659},{"cath_id":"3.10.20.90","chopping":"860-947","consensus_level":"medium","plddt":87.025,"start":860,"end":947}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99558","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99558-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99558-F1-predicted_aligned_error_v6.png","plddt_mean":60.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MAP3K14","jax_strain_url":"https://www.jax.org/strain/search?query=MAP3K14"},"sequence":{"accession":"Q99558","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99558.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99558/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99558"}},"corpus_meta":[{"pmid":"18997792","id":"PMC_18997792","title":"Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling.","date":"2008","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18997792","citation_count":524,"is_preprint":false},{"pmid":"11251123","id":"PMC_11251123","title":"Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice.","date":"2001","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/11251123","citation_count":325,"is_preprint":false},{"pmid":"12598905","id":"PMC_12598905","title":"Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade.","date":"2003","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12598905","citation_count":243,"is_preprint":false},{"pmid":"18292232","id":"PMC_18292232","title":"Control of canonical NF-kappaB activation through the NIK-IKK complex pathway.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18292232","citation_count":165,"is_preprint":false},{"pmid":"11254583","id":"PMC_11254583","title":"Micrococci and peptidoglycan activate TLR2-->MyD88-->IRAK-->TRAF-->NIK-->IKK-->NF-kappaB signal transduction pathway that induces transcription of interleukin-8.","date":"2001","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11254583","citation_count":140,"is_preprint":false},{"pmid":"9826717","id":"PMC_9826717","title":"Fetuin (alpha2-HS-glycoprotein) opsonizes cationic macrophagedeactivating molecules.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9826717","citation_count":138,"is_preprint":false},{"pmid":"33187137","id":"PMC_33187137","title":"Targeting NF-κB-Inducing Kinase (NIK) in Immunity, Inflammation, and Cancer.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33187137","citation_count":136,"is_preprint":false},{"pmid":"16461467","id":"PMC_16461467","title":"An RNA interference-based screen identifies MAP4K4/NIK as a negative regulator of PPARgamma, adipogenesis, and insulin-responsive hexose transport.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16461467","citation_count":135,"is_preprint":false},{"pmid":"21273489","id":"PMC_21273489","title":"Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation.","date":"2011","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/21273489","citation_count":127,"is_preprint":false},{"pmid":"12604602","id":"PMC_12604602","title":"The involvement of heparan sulfate (HS) in FGF1/HS/FGFR1 signaling complex.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12604602","citation_count":125,"is_preprint":false},{"pmid":"18322009","id":"PMC_18322009","title":"RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18322009","citation_count":121,"is_preprint":false},{"pmid":"25406581","id":"PMC_25406581","title":"Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25406581","citation_count":111,"is_preprint":false},{"pmid":"22105365","id":"PMC_22105365","title":"MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-κB-inducing kinase (NIK).","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22105365","citation_count":105,"is_preprint":false},{"pmid":"15951441","id":"PMC_15951441","title":"NIBP, a novel NIK and IKK(beta)-binding protein that enhances NF-(kappa)B activation.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15951441","citation_count":104,"is_preprint":false},{"pmid":"22581287","id":"PMC_22581287","title":"NF-κB–inducing kinase (NIK) promotes hyperglycemia and glucose intolerance in obesity by augmenting glucagon action.","date":"2012","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22581287","citation_count":90,"is_preprint":false},{"pmid":"15147892","id":"PMC_15147892","title":"NF-kappaB activation mechanism of 4-hydroxyhexenal via NIK/IKK and p38 MAPK pathway.","date":"2004","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/15147892","citation_count":85,"is_preprint":false},{"pmid":"25088600","id":"PMC_25088600","title":"Mouse hepatocyte overexpression of NF-κB-inducing kinase (NIK) triggers fatal macrophage-dependent liver injury and fibrosis.","date":"2014","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/25088600","citation_count":84,"is_preprint":false},{"pmid":"16223731","id":"PMC_16223731","title":"Stabilization of basally translated NF-kappaB-inducing kinase (NIK) protein functions as a molecular switch of processing of NF-kappaB2 p100.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16223731","citation_count":80,"is_preprint":false},{"pmid":"37769558","id":"PMC_37769558","title":"Characterization and metabolism pathway of volatile compounds in walnut oil obtained from various ripening stages via HS-GC-IMS and HS-SPME-GC-MS.","date":"2023","source":"Food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37769558","citation_count":79,"is_preprint":false},{"pmid":"27889261","id":"PMC_27889261","title":"NIK/MAP3K14 Regulates Mitochondrial Dynamics and Trafficking to Promote Cell Invasion.","date":"2016","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/27889261","citation_count":77,"is_preprint":false},{"pmid":"11290295","id":"PMC_11290295","title":"Mesodermal patterning defect in mice lacking the Ste20 NCK interacting kinase (NIK).","date":"2001","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/11290295","citation_count":76,"is_preprint":false},{"pmid":"37165186","id":"PMC_37165186","title":"EDA2R-NIK signalling promotes muscle atrophy linked to cancer cachexia.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/37165186","citation_count":74,"is_preprint":false},{"pmid":"24459635","id":"PMC_24459635","title":"Post-Synthetic Regulation of HS Structure: The Yin and Yang of the Sulfs in Cancer.","date":"2014","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24459635","citation_count":74,"is_preprint":false},{"pmid":"22469134","id":"PMC_22469134","title":"Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma.","date":"2012","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/22469134","citation_count":73,"is_preprint":false},{"pmid":"19411637","id":"PMC_19411637","title":"Regulation of Th17 cell differentiation and EAE induction by MAP3K NIK.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19411637","citation_count":73,"is_preprint":false},{"pmid":"27871061","id":"PMC_27871061","title":"A small-molecule inhibitor of NF-κB-inducing kinase (NIK) protects liver from toxin-induced inflammation, oxidative stress, and injury.","date":"2016","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/27871061","citation_count":67,"is_preprint":false},{"pmid":"22968463","id":"PMC_22968463","title":"Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22968463","citation_count":66,"is_preprint":false},{"pmid":"20348096","id":"PMC_20348096","title":"Allosteric regulation of the ubiquitin:NIK and ubiquitin:TRAF3 E3 ligases by the lymphotoxin-beta receptor.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20348096","citation_count":65,"is_preprint":false},{"pmid":"18789471","id":"PMC_18789471","title":"The ribosomal protein L10/QM-like protein is a component of the NIK-mediated antiviral signaling.","date":"2008","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/18789471","citation_count":64,"is_preprint":false},{"pmid":"20624762","id":"PMC_20624762","title":"NSP-interacting kinase, NIK: a transducer of plant defence signalling.","date":"2010","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/20624762","citation_count":60,"is_preprint":false},{"pmid":"28400474","id":"PMC_28400474","title":"Suppression of Th17 cell differentiation by misshapen/NIK-related kinase MINK1.","date":"2017","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28400474","citation_count":60,"is_preprint":false},{"pmid":"21151480","id":"PMC_21151480","title":"NIK stabilization in osteoclasts results in osteoporosis and enhanced inflammatory osteolysis.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21151480","citation_count":57,"is_preprint":false},{"pmid":"29607540","id":"PMC_29607540","title":"Melatonin improves insulin resistance and hepatic steatosis through attenuation of alpha-2-HS-glycoprotein.","date":"2018","source":"Journal of pineal research","url":"https://pubmed.ncbi.nlm.nih.gov/29607540","citation_count":57,"is_preprint":false},{"pmid":"30237400","id":"PMC_30237400","title":"HS-1371, a novel kinase inhibitor of RIP3-mediated necroptosis.","date":"2018","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30237400","citation_count":54,"is_preprint":false},{"pmid":"19672022","id":"PMC_19672022","title":"High glucose induces transactivation of the alpha2-HS glycoprotein gene through the ERK1/2 signaling pathway.","date":"2009","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/19672022","citation_count":52,"is_preprint":false},{"pmid":"12884866","id":"PMC_12884866","title":"Caspase-8 and caspase-10 activate NF-kappaB through RIP, NIK and IKKalpha kinases.","date":"2003","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12884866","citation_count":50,"is_preprint":false},{"pmid":"11133934","id":"PMC_11133934","title":"Identification of the nik gene cluster of Brucella suis: regulation and contribution to urease activity.","date":"2001","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/11133934","citation_count":47,"is_preprint":false},{"pmid":"22718757","id":"PMC_22718757","title":"Structure of the nuclear factor κB-inducing kinase (NIK) kinase domain reveals a constitutively active conformation.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22718757","citation_count":46,"is_preprint":false},{"pmid":"28688971","id":"PMC_28688971","title":"Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/28688971","citation_count":46,"is_preprint":false},{"pmid":"21846802","id":"PMC_21846802","title":"NF-kappaB-inducing kinase (NIK) mediates skeletal muscle insulin resistance: blockade by adiponectin.","date":"2011","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21846802","citation_count":45,"is_preprint":false},{"pmid":"26561586","id":"PMC_26561586","title":"Dendritic cells require NIK for CD40-dependent cross-priming of CD8+ T cells.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26561586","citation_count":45,"is_preprint":false},{"pmid":"20580552","id":"PMC_20580552","title":"NF-kappaB inducing kinase (NIK) inhibitors: identification of new scaffolds using virtual screening.","date":"2010","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/20580552","citation_count":44,"is_preprint":false},{"pmid":"21887257","id":"PMC_21887257","title":"NF-κB inducing kinase, NIK mediates cigarette smoke/TNFα-induced histone acetylation and inflammation through differential activation of IKKs.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21887257","citation_count":43,"is_preprint":false},{"pmid":"23301098","id":"PMC_23301098","title":"Downregulation of TRAF2 mediates NIK-induced pancreatic cancer cell proliferation and tumorigenicity.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23301098","citation_count":40,"is_preprint":false},{"pmid":"26045047","id":"PMC_26045047","title":"NIK promotes tissue destruction independently of the alternative NF-κB pathway through TNFR1/RIP1-induced apoptosis.","date":"2015","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/26045047","citation_count":40,"is_preprint":false},{"pmid":"30250187","id":"PMC_30250187","title":"NIK signaling axis regulates dendritic cell function in intestinal immunity and homeostasis.","date":"2018","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30250187","citation_count":39,"is_preprint":false},{"pmid":"26598717","id":"PMC_26598717","title":"Misshapen/NIK-related kinase (MINK1) is involved in platelet function, hemostasis, and thrombus formation.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/26598717","citation_count":39,"is_preprint":false},{"pmid":"36042192","id":"PMC_36042192","title":"Biliary NIK promotes ductular reaction and liver injury and fibrosis in mice.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36042192","citation_count":37,"is_preprint":false},{"pmid":"20466000","id":"PMC_20466000","title":"Lipopolysaccharide-induced activation of NF-κB non-canonical pathway requires BCL10 serine 138 and NIK phosphorylations.","date":"2010","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/20466000","citation_count":37,"is_preprint":false},{"pmid":"30018345","id":"PMC_30018345","title":"A TRAF3-NIK module differentially regulates DNA vs RNA pathways in innate immune signaling.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30018345","citation_count":36,"is_preprint":false},{"pmid":"19646419","id":"PMC_19646419","title":"NIK is involved in constitutive activation of the alternative NF-kappaB pathway and proliferation of pancreatic cancer cells.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19646419","citation_count":36,"is_preprint":false},{"pmid":"16971398","id":"PMC_16971398","title":"Improving solubility and refolding efficiency of human V(H)s by a novel mutational approach.","date":"2006","source":"Protein engineering, design & selection : PEDS","url":"https://pubmed.ncbi.nlm.nih.gov/16971398","citation_count":35,"is_preprint":false},{"pmid":"18068231","id":"PMC_18068231","title":"Differential regulation of IKK alpha-mediated activation of IRF3/7 by NIK.","date":"2007","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18068231","citation_count":35,"is_preprint":false},{"pmid":"25601402","id":"PMC_25601402","title":"The Nck-interacting kinase NIK increases Arp2/3 complex activity by phosphorylating the Arp2 subunit.","date":"2015","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25601402","citation_count":34,"is_preprint":false},{"pmid":"27905294","id":"PMC_27905294","title":"Glucocorticoids increase skeletal muscle NF-κB inducing kinase (NIK): links to muscle atrophy.","date":"2016","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/27905294","citation_count":33,"is_preprint":false},{"pmid":"27793006","id":"PMC_27793006","title":"HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27793006","citation_count":33,"is_preprint":false},{"pmid":"8738720","id":"PMC_8738720","title":"Antibodies to endometrial transferrin and alpha 2-Heremans Schmidt (HS) glycoprotein in patients with endometriosis.","date":"1996","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/8738720","citation_count":33,"is_preprint":false},{"pmid":"38677244","id":"PMC_38677244","title":"NETs induce ferroptosis of endothelial cells in LPS-ALI through SDC-1/HS and downstream pathways.","date":"2024","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/38677244","citation_count":32,"is_preprint":false},{"pmid":"23742758","id":"PMC_23742758","title":"Combined Cathepsin S and hs-CRP predicting inflammation of abdominal aortic aneurysm.","date":"2013","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23742758","citation_count":32,"is_preprint":false},{"pmid":"23954076","id":"PMC_23954076","title":"Ceriponols A-K, tremulane sesquitepenes from Ceriporia lacerate HS-ZJUT-C13A, a fungal endophyte of Huperzia serrata.","date":"2013","source":"Phytochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23954076","citation_count":31,"is_preprint":false},{"pmid":"30070632","id":"PMC_30070632","title":"Hepatic NF-kB-inducing kinase (NIK) suppresses mouse liver regeneration in acute and chronic liver diseases.","date":"2018","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/30070632","citation_count":31,"is_preprint":false},{"pmid":"32494901","id":"PMC_32494901","title":"Nitric oxide and TNF-α are correlates of diabetic retinopathy independent of hs-CRP and HbA1c.","date":"2020","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/32494901","citation_count":31,"is_preprint":false},{"pmid":"12853971","id":"PMC_12853971","title":"NIK is a component of the EGF/heregulin receptor signaling complexes.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12853971","citation_count":30,"is_preprint":false},{"pmid":"10433073","id":"PMC_10433073","title":"Levels of transferrin and alpha 2-HS glycoprotein in women with and without endometriosis.","date":"1999","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/10433073","citation_count":30,"is_preprint":false},{"pmid":"12203946","id":"PMC_12203946","title":"Alpha2-HS glycoprotein: a protein in search of a function.","date":"2002","source":"Diabetes/metabolism research and reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12203946","citation_count":29,"is_preprint":false},{"pmid":"35031599","id":"PMC_35031599","title":"NEK2 enhances malignancies of glioblastoma via NIK/NF-κB pathway.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35031599","citation_count":28,"is_preprint":false},{"pmid":"32318065","id":"PMC_32318065","title":"HS and Inflammation: A Potential Playground for the Sulfs?","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32318065","citation_count":27,"is_preprint":false},{"pmid":"21490678","id":"PMC_21490678","title":"SMG1 and NIK regulate apoptosis induced by Smac mimetic compounds.","date":"2011","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/21490678","citation_count":26,"is_preprint":false},{"pmid":"30260015","id":"PMC_30260015","title":"Adipose tissue-derived stem cells inhibit hypertrophic scar (HS) fibrosis via p38/MAPK pathway.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30260015","citation_count":25,"is_preprint":false},{"pmid":"25246529","id":"PMC_25246529","title":"Nuclear factor-κB-inducing kinase (NIK) contains an amino-terminal inhibitor of apoptosis (IAP)-binding motif (IBM) that potentiates NIK degradation by cellular IAP1 (c-IAP1).","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25246529","citation_count":24,"is_preprint":false},{"pmid":"25887393","id":"PMC_25887393","title":"GAG-ID: Heparan Sulfate (HS) and Heparin Glycosaminoglycan High-Throughput Identification Software.","date":"2015","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/25887393","citation_count":24,"is_preprint":false},{"pmid":"21385462","id":"PMC_21385462","title":"Characterisation of the legume SERK-NIK gene superfamily including splice variants: implications for development and defence.","date":"2011","source":"BMC plant biology","url":"https://pubmed.ncbi.nlm.nih.gov/21385462","citation_count":24,"is_preprint":false},{"pmid":"22284830","id":"PMC_22284830","title":"The relationship between hs-CRP and asthma control test in asthmatic patients.","date":"2012","source":"Allergologia et immunopathologia","url":"https://pubmed.ncbi.nlm.nih.gov/22284830","citation_count":24,"is_preprint":false},{"pmid":"28652181","id":"PMC_28652181","title":"gga-miR-99a targets SMARCA5 to regulate Mycoplasma gallisepticum (HS strain) infection by depressing cell proliferation in chicken.","date":"2017","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/28652181","citation_count":23,"is_preprint":false},{"pmid":"28512626","id":"PMC_28512626","title":"Anti-Restriction Protein, KlcAHS, Promotes Dissemination of Carbapenem Resistance.","date":"2017","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/28512626","citation_count":22,"is_preprint":false},{"pmid":"29259025","id":"PMC_29259025","title":"Noncanonical NF-κB signaling and the essential kinase NIK modulate crucial features associated with eosinophilic esophagitis pathogenesis.","date":"2017","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/29259025","citation_count":22,"is_preprint":false},{"pmid":"32479083","id":"PMC_32479083","title":"Identification of N-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives as Novel, Potent, and Selective NF-κB Inducing Kinase (NIK) Inhibitors for the Treatment of Psoriasis.","date":"2020","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32479083","citation_count":22,"is_preprint":false},{"pmid":"20818435","id":"PMC_20818435","title":"The RET/PTC3 oncogene activates classical NF-κB by stabilizing NIK.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20818435","citation_count":22,"is_preprint":false},{"pmid":"32434006","id":"PMC_32434006","title":"Emerging role of NIK/IKK2-binding protein (NIBP)/trafficking protein particle complex 9 (TRAPPC9) in nervous system diseases.","date":"2020","source":"Translational research : the journal of laboratory and clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32434006","citation_count":21,"is_preprint":false},{"pmid":"25079338","id":"PMC_25079338","title":"Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.","date":"2014","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/25079338","citation_count":21,"is_preprint":false},{"pmid":"34046627","id":"PMC_34046627","title":"Pharmacological inhibition of NF-κB-inducing kinase (NIK) with small molecules for the treatment of human diseases.","date":"2021","source":"RSC medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34046627","citation_count":21,"is_preprint":false},{"pmid":"25812680","id":"PMC_25812680","title":"Downregulation of miR-518a-3p activates the NIK-dependent NF-κB pathway in colorectal cancer.","date":"2015","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25812680","citation_count":20,"is_preprint":false},{"pmid":"15016648","id":"PMC_15016648","title":"Deletion of the major GATA1 enhancer HS 1 does not affect eosinophil GATA1 expression and eosinophil differentiation.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15016648","citation_count":20,"is_preprint":false},{"pmid":"36317784","id":"PMC_36317784","title":"Spatiotemporal tracking of small extracellular vesicle nanotopology in response to physicochemical stresses revealed by HS-AFM.","date":"2022","source":"Journal of extracellular vesicles","url":"https://pubmed.ncbi.nlm.nih.gov/36317784","citation_count":20,"is_preprint":false},{"pmid":"40221654","id":"PMC_40221654","title":"Correlation between hs-CRP-triglyceride glucose index and NAFLD and liver fibrosis.","date":"2025","source":"BMC gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/40221654","citation_count":19,"is_preprint":false},{"pmid":"37453477","id":"PMC_37453477","title":"EGR1 knockdown confers protection against ferroptosis and ameliorates intervertebral disc cartilage degeneration by inactivating the MAP3K14/NF-κB axis.","date":"2023","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/37453477","citation_count":19,"is_preprint":false},{"pmid":"35745045","id":"PMC_35745045","title":"Quality and Metabolomics Analysis of Houttuynia cordata Based on HS-SPME/GC-MS.","date":"2022","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35745045","citation_count":19,"is_preprint":false},{"pmid":"100151","id":"PMC_100151","title":"Linkage and gene localization of hereditary spherocytosis (HS).","date":"1978","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/100151","citation_count":19,"is_preprint":false},{"pmid":"29503445","id":"PMC_29503445","title":"Lymphatic endothelial cells regulate B-cell homing to lymph nodes via a NIK-dependent mechanism.","date":"2018","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29503445","citation_count":18,"is_preprint":false},{"pmid":"31137698","id":"PMC_31137698","title":"gga-miR-146c Activates TLR6/MyD88/NF-κB Pathway through Targeting MMP16 to Prevent Mycoplasma Gallisepticum (HS Strain) Infection in Chickens.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31137698","citation_count":18,"is_preprint":false},{"pmid":"29230214","id":"PMC_29230214","title":"Exome Sequencing Identifies a Novel MAP3K14 Mutation in Recessive Atypical Combined Immunodeficiency.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29230214","citation_count":17,"is_preprint":false},{"pmid":"36119471","id":"PMC_36119471","title":"Potentially functional variants of MAP3K14 in the NF-κB signaling pathway genes predict survival of HBV-related hepatocellular carcinoma patients.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36119471","citation_count":17,"is_preprint":false},{"pmid":"31585644","id":"PMC_31585644","title":"gga-miR-21 modulates Mycoplasma gallisepticum (HS strain)-Induced inflammation via targeting MAP3K1 and activating MAPKs and NF-κB pathways.","date":"2019","source":"Veterinary microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/31585644","citation_count":17,"is_preprint":false},{"pmid":"24862492","id":"PMC_24862492","title":"HS-23, Lonicera japonica extract, attenuates septic injury by suppressing toll-like receptor 4 signaling.","date":"2014","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24862492","citation_count":17,"is_preprint":false},{"pmid":"38685821","id":"PMC_38685821","title":"Gram-negative anaerobes elicit a robust keratinocytes immune response with potential insights into HS pathogenesis.","date":"2024","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/38685821","citation_count":16,"is_preprint":false},{"pmid":"21204728","id":"PMC_21204728","title":"The kinase NIK as a therapeutic target in multiple myeloma.","date":"2011","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/21204728","citation_count":16,"is_preprint":false},{"pmid":"31455723","id":"PMC_31455723","title":"SMAC mimetics promote NIK-dependent inhibition of CD4+ TH17 cell differentiation.","date":"2019","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/31455723","citation_count":16,"is_preprint":false},{"pmid":"33623121","id":"PMC_33623121","title":"MicroRNA-17-3p suppresses NF-κB-mediated endothelial inflammation by targeting NIK and IKKβ binding protein.","date":"2021","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/33623121","citation_count":16,"is_preprint":false},{"pmid":"25943882","id":"PMC_25943882","title":"Lowering the quantification limit of the QubitTM RNA HS assay using RNA spike-in.","date":"2015","source":"BMC molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25943882","citation_count":16,"is_preprint":false},{"pmid":"34715577","id":"PMC_34715577","title":"Exosomal miR-181a-5p reduce Mycoplasma gallisepticum (HS strain) infection in chicken by targeting PPM1B and activating the TLR2-mediated MyD88/NF-κB signaling pathway.","date":"2021","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34715577","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49191,"output_tokens":8305,"usd":0.136074},"stage2":{"model":"claude-opus-4-6","input_tokens":12368,"output_tokens":4908,"usd":0.27681},"total_usd":0.412884,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"TRAF2 and TRAF3 form a ubiquitin ligase complex with cIAP1/cIAP2 that constitutively targets NIK (MAP3K14) for proteasomal degradation; receptor activation (CD40 or BAFF-R) triggers TRAF2-mediated K63-linked ubiquitination and activation of cIAP1/cIAP2, redirecting their E3 ligase activity to degrade TRAF3, thereby releasing NIK from the complex, stabilizing it, and enabling NF-κB2/p100 processing to p52.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, TRAF3-deficient and TRAF2-deficient cell lines, mouse genetic models\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal biochemical assays plus genetic models, independently replicated across several labs\",\n      \"pmids\": [\"18997792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"NIK is selectively required for NF-κB transcriptional activation downstream of the lymphotoxin-β receptor (LTβR) but not downstream of TNF receptor or IL-1 receptor; NIK knockout mice show defects in lymphoid tissue development and antibody responses.\",\n      \"method\": \"Gene targeting/knockout mouse, NF-κB DNA binding assays, cytokine stimulation of NIK-/- cells, reporter gene assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular and molecular phenotype, published in high-impact journal\",\n      \"pmids\": [\"11251123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Crystal structure of the truncated human NIK kinase domain (with N-terminal extension) in complex with ATPγS at 2.5 Å reveals a constitutively active conformation that does not require phosphorylation; the N-terminal extension stabilizes helix αC in the active orientation, explaining NIK's intrinsic constitutive kinase activity and the gain-of-function of N-terminal deletion mutants.\",\n      \"method\": \"X-ray crystallography, kinase activity assays, mutational analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional validation\",\n      \"pmids\": [\"22718757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The API2-MALT1 fusion oncoprotein proteolytically cleaves NIK at arginine 325; both API2 and MALT1 partners are required, and the resulting C-terminal NIK fragment retains kinase activity, is resistant to proteasomal degradation, and drives constitutive noncanonical NF-κB signaling, enhanced B-cell adhesion, and apoptosis resistance.\",\n      \"method\": \"Biochemical cleavage assays, mutagenesis (Arg325 site), co-expression experiments, NF-κB reporter assays, apoptosis/adhesion assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — site-specific cleavage mapped with mutagenesis, multiple functional readouts\",\n      \"pmids\": [\"21273489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Recruitment of TRAF3 and TRAF2 to the ligated LTβR competitively displaces NIK from the TRAF3-binding site (shown by charge-repulsion mutation ablating both LTβR and NIK binding to TRAF3); ligated LTβR also allosterically redirects the ubiquitin:NIK E3 ligase to polyubiquitinate and degrade TRAF3/TRAF2 via the RING domain of TRAF2, thereby halting NIK turnover and promoting NIK association with IKKα.\",\n      \"method\": \"Mutagenesis of TRAF3/TRAF2 receptor-binding domains, co-immunoprecipitation, ubiquitination assays, LTβR signaling reconstitution\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis combined with biochemical reconstitution defining a competitive displacement mechanism\",\n      \"pmids\": [\"20348096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NIK contains an IAP-binding motif (IBM) at its amino terminus that interacts with the BIR2 domain of c-IAP1, providing substrate recognition for c-IAP1-mediated ubiquitylation and proteasomal degradation of NIK; IBM mutation stabilizes NIK and constitutively elevates p100-to-p52 processing and NF-κB target gene expression.\",\n      \"method\": \"Mutagenesis of the NIK IBM, co-immunoprecipitation with c-IAP1 BIR2 domain, ubiquitylation assays, NF-κB reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis of a defined motif combined with biochemical ubiquitylation assay and functional NF-κB readout\",\n      \"pmids\": [\"25246529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"NIK protein undergoes constitutive synthesis but rapid proteasomal degradation in resting B cells; BAFF and CD40L stabilize basally translated NIK post-translationally (without increasing mRNA or translation rate), and stabilized NIK is sufficient to trigger p100-to-p52 processing even in the presence of a protein synthesis inhibitor.\",\n      \"method\": \"Pulse-chase experiments, protein synthesis inhibitor treatment, immunoblot for NIK and p100/p52, stimulation with BAFF/CD40L vs. TNFα/PMA\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal biochemical methods defining the post-translational regulation mechanism\",\n      \"pmids\": [\"16223731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"NIK (MAP3K14) is localized to mitochondria in cancer cells and MEFs; NIK promotes mitochondrial fission and directional migration by recruiting Drp1 to mitochondria, forming a complex with Drp1, and regulating Drp1 phosphorylation (Ser-616) and dephosphorylation (Ser-637); this function is independent of IKKα/β and NF-κB.\",\n      \"method\": \"Subcellular fractionation, live-cell imaging, co-immunoprecipitation (NIK-Drp1 complex), Drp1 phosphorylation assays, IKK/NF-κB-null MEFs, invasion assays\",\n      \"journal\": \"Current biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization with functional consequence, complex identified by Co-IP, IKK-independence established by genetic epistasis\",\n      \"pmids\": [\"27889261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NIK (MAP4K4) binds and directly phosphorylates the Arp2 subunit of the Arp2/3 complex, increasing its nucleating activity; NIK kinase activity is necessary for EGF-stimulated Arp2 phosphorylation and plasma membrane protrusion in mammary carcinoma cells.\",\n      \"method\": \"In vitro kinase assay (recombinant NIK phosphorylating Arp2), co-immunoprecipitation, phospho-mimetic/phospho-dead Arp2 mutants, actin assembly assays, EGF stimulation of cells\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay with mutagenesis and functional actin assembly readout\",\n      \"pmids\": [\"25601402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"MAP4K4/NIK (the Ste20-related kinase, not the NF-κB-inducing kinase) is essential for mesodermal and endodermal cell migration during gastrulation; NIK-null mouse embryos die at E9.5-10.5 with failure of presomitic mesodermal cells to migrate from the primitive streak; chimeric analysis reveals both cell-nonautonomous (migration stimulation) and cell-autonomous (dermomyotome differentiation) functions.\",\n      \"method\": \"Homologous recombination knockout, embryo phenotype analysis, chimeric mouse analysis\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined developmental phenotype and chimeric rescue dissecting cell-autonomous vs non-autonomous roles\",\n      \"pmids\": [\"11290295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TRAF3 depletion leads to accumulation of NIK, which then activates both canonical (p50-dependent) and noncanonical (p52-dependent) NF-κB pathways; deregulated canonical NF-κB activation in TRAF3-deficient cells is dependent on NIK accumulation.\",\n      \"method\": \"TRAF3-deficient cell lines, NIK knockdown/overexpression, NF-κB reporter assays, EMSA, immunoblot for p100/p52 processing\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (TRAF3 KO rescued by NIK depletion) with multiple NF-κB readouts\",\n      \"pmids\": [\"18292232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"NIK is required for osteoclast differentiation; NIK deficiency blocks both alternative and classical NF-κB due to cytoplasmic p100 retention; p100 deletion or RelB overexpression (but not p65) rescues osteoclastogenesis in NIK-/- precursors; RelB-/- mice show impaired osteoclast formation and reduced tumor-induced osteolysis.\",\n      \"method\": \"NIK-/- and RelB-/- mouse osteoclast cultures, retroviral overexpression of RelB/p65, in vivo serum transfer/tumor models, bone histomorphometry\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with specific rescue experiments and in vivo validation\",\n      \"pmids\": [\"18322009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NIK promotes glucagon-stimulated hepatic glucose production in obesity by increasing cAMP response element-binding protein (CREB) stability; hepatic NIK is abnormally activated in obese mice; liver-specific inhibition of NIK reduces glucagon responses and HGP, while hepatocyte-specific NIK overexpression increases them.\",\n      \"method\": \"Map3k14 systemic knockout, liver-specific NIK deletion, hepatocyte-specific NIK transgene, primary hepatocyte glucose production assays, CREB stability assays\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic models (KO, conditional KO, transgene) with defined molecular mechanism (CREB stability)\",\n      \"pmids\": [\"22581287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"NIK is required for Th17 cell differentiation; NIK-deficient naive CD4+ T cells are defective in Th17 commitment but not other lineages; NIK mediates synergistic STAT3 activation by TCR and IL-6 receptor signals, and its loss attenuates STAT3 phosphorylation and STAT3 target gene induction needed for Th17 commitment; NIK-/- mice are resistant to EAE.\",\n      \"method\": \"NIK-/- mouse T-cell differentiation assays, Rag2-/- reconstitution with NIK-/- T cells, STAT3 phosphorylation assays, EAE model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with T-cell-intrinsic reconstitution proof and molecular STAT3 mechanism\",\n      \"pmids\": [\"19411637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Biallelic loss-of-function mutations in MAP3K14 (NIK) cause primary immunodeficiency in humans; mutant NIK loses kinase activity (confirmed by functional assays), leading to defective canonical and noncanonical NF-κB activation, B-cell lymphopenia, impaired ICOSL expression, perturbed follicular helper and memory T cells, and defective NK-cell immunological synapse formation.\",\n      \"method\": \"Patient genetics, NIK kinase activity assays, NF-κB signaling assays, flow cytometry of lymphocyte subsets, NK-cell immunological synapse imaging\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human loss-of-function with in vitro kinase assay confirmation and multiple immune functional readouts\",\n      \"pmids\": [\"25406581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NIK interacts with the innate DNA-sensing adaptor STING independently of alternative NF-κB signaling components; NIK autophosphorylation and oligomerization are required to activate STING-dependent IFN induction; NIK-deficient mice are more susceptible to DNA virus infection; TRAF3, a positive regulator of RNA-pathway IFN, inhibits the DNA pathway by limiting NIK availability.\",\n      \"method\": \"NIK-/- mouse infection models, co-immunoprecipitation of NIK-STING, autophosphorylation assays, NIK oligomerization assays, IFN reporter assays, epistasis with alternative NF-κB components\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, in vitro kinase assays, in vivo infection model, epistasis experiments\",\n      \"pmids\": [\"30018345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NIK confers IKKα the ability to activate IRF3/7 for IFN production; NIK phosphorylates IKKα at Ser-176 and Ser-180, but these two phosphorylations have differential effects: IKKα(S176E) constitutively activates IRF3/7 while IKKα(S180E) loses this ability, revealing that NIK differentially regulates NF-κB versus IRF3/7 activation through IKKα.\",\n      \"method\": \"Phosphomimetic IKKα mutagenesis (S176E, S180E), IRF3/7 reporter assays, TLR7/9 stimulation, kinase assays\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — site-specific mutagenesis with differential functional outcomes establishes mechanism\",\n      \"pmids\": [\"18068231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"NIK physically interacts with IKKβ (but not IKKα or IKKγ) and with a novel brain-enriched protein NIBP (identified by yeast two-hybrid screen); NIBP overexpression potentiates TNFα-induced NF-κB activation through increased IKK complex phosphorylation and downstream IκBα/p65 phosphorylation, while NIBP knockdown reduces NF-κB activation.\",\n      \"method\": \"Yeast two-hybrid screen, co-immunoprecipitation, overexpression/siRNA knockdown in PC12 cells, NF-κB reporter assays, phosphorylation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — yeast two-hybrid plus single Co-IP; functional follow-up supports interaction\",\n      \"pmids\": [\"15951441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"NIK is a component of EGF/heregulin receptor signaling complexes; NIK interacts with Grb7 (via Grb7's GM domain), Grb10, and Grb14, and can be simultaneously recruited with Grb7 into EGFR, ErbB2, ErbB3, and ErbB4 complexes; NIK potentiates EGF/heregulin-induced NF-κB activation, and EGF activates NF-κB in wild-type but not NIK-/- fibroblasts.\",\n      \"method\": \"Antibody array screen for NIK-associated proteins, co-immunoprecipitation, domain mapping (Grb7 GM domain), NF-κB reporter assays in NIK-/- MEFs\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — antibody array + Co-IP + NIK-/- genetic test; solid but single lab\",\n      \"pmids\": [\"12853971\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Cytokine (IL-1/TNFα)-induced suppression of PPAR-γ adipogenic function is mediated through the TAK1/TAB1/NIK cascade activating NF-κB; NF-κB blocks PPAR-γ DNA binding by forming a complex with PPAR-γ and its AF-1-specific co-activator PGC-2.\",\n      \"method\": \"Dominant-negative kinase constructs, NF-κB reporter assays, co-immunoprecipitation of NF-κB/PPAR-γ/PGC-2 complex, PPAR-γ DNA binding assays, adipogenesis assays\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — dominant-negative epistasis combined with complex Co-IP, but TAK1/TAB1 aspects complicate direct NIK attribution\",\n      \"pmids\": [\"12598905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NIK promotes TNFR1-mediated RIP1-dependent apoptosis independently of alternative NF-κB (p100-to-p52 processing); NIK stabilization (via Fn14 or LTβR) is required for TNFα-induced cIAP1/2 depletion to trigger RIP1 phosphorylation and RIP1/FADD/caspase-8 complex assembly; in vitro kinase assays show RIP1 is a direct NIK substrate.\",\n      \"method\": \"In vitro kinase assay (NIK phosphorylating RIP1), genetic models (NIK-/- and p100-/- mice), thymus involution and liver damage in vivo models, immunoprecipitation of RIP1/FADD/caspase-8 complex\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro kinase assay identifying RIP1 as NIK substrate, with in vivo genetic validation\",\n      \"pmids\": [\"26045047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"NIK mediates NF-κB activation downstream of caspase-8 and caspase-10 prodomain isoforms (PDCasp8/10); GST pulldown shows NIK (and RIP) directly bind PDCasp8/10; dominant-negative IKKα or kinase-dead RIP blocks PDCasp8/10-mediated NF-κB activation; siRNA knockdown shows IKKα (not IKKβ) is the relevant downstream kinase.\",\n      \"method\": \"GST pulldown, dominant-negative mutants, siRNA knockdown, NF-κB reporter assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — GST pulldown with functional dominant-negative and siRNA validation; single lab\",\n      \"pmids\": [\"12884866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NIK promotes liver inflammation and fibrosis through a hepatocyte NIK-liver immune cell (macrophage) axis; hepatocyte NIK overexpression stimulates release of chemokines/cytokines that activate macrophages, which in turn secrete proapoptotic factors inducing hepatocyte apoptosis; depletion of Kupffer cells/macrophages reverses NIK-induced liver destruction.\",\n      \"method\": \"Hepatocyte-specific NIK transgene, primary hepatocyte conditioned medium experiments, macrophage activation assays, Kupffer cell depletion, liver histology/fibrosis assays\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — transgenic model with mechanistic dissection (macrophage depletion rescue), multiple orthogonal readouts\",\n      \"pmids\": [\"25088600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NIK (MAP3K14) and its substrate IKKα suppress the mitogenic JAK2/STAT3 pathway to restrain hepatocyte proliferation and liver regeneration; hepatocyte-specific deletion of Map3k14 or Chuk (IKKα) substantially accelerates hepatocyte proliferation after partial hepatectomy, even under liver disease conditions (hepatotoxin or high-fat diet).\",\n      \"method\": \"Hepatocyte-specific Map3k14 and Chuk knockout mice, partial hepatectomy, STAT3/JAK2 phosphorylation assays, cell cycle analysis, liver disease models\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO of both NIK and its substrate IKKα with defined JAK2/STAT3 mechanism and multiple disease models\",\n      \"pmids\": [\"30070632\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"NIK stabilization in osteoclast precursors (via deletion of TRAF3-binding domain) constitutively activates alternative NF-κB and enhances both osteoclast differentiation speed and resorptive function, causing high-turnover osteoporosis and exaggerated inflammatory osteolysis in vivo.\",\n      \"method\": \"OC-lineage transgenic mice expressing TRAF3-binding-deficient NIK (NT3), in vitro osteoclastogenesis assays, bone resorption/actin ring measurements, serum transfer arthritis model\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — transgenic gain-of-function with defined NF-κB mechanism and multiple in vivo/in vitro readouts\",\n      \"pmids\": [\"21151480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"EDA-A2 ligand activates EDA2R receptor signaling that requires NIK activity to promote skeletal muscle atrophy; EDA-A2 stimulation induces noncanonical NF-κB pathway activation and upregulates Atrogin1/MuRF1; muscle-specific NIK deletion protects tumour-bearing mice from cancer cachexia-associated muscle wasting; oncostatin M (OSM) upregulates muscle EDA2R expression upstream of NIK.\",\n      \"method\": \"Primary myotube EDA-A2 stimulation assays, muscle-specific NIK knockout mice, EDA2R knockout mice, tumour-bearing mouse cachexia model, NIK kinase inhibitor treatment, OSMR muscle-specific KO\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple conditional KO models with in vivo functional validation of EDA2R-NIK axis\",\n      \"pmids\": [\"37165186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Biliary NIK promotes ductular reaction independently of its canonical substrate IKKα; cholangiocyte-specific NIK deletion (but not IKKα deletion) blunts cholestasis-induced ductular reaction, liver injury, inflammation and fibrosis; NIK directly increases cholangiocyte proliferation, suppresses their death, and stimulates secretion of cholangiokines that activate macrophages and hepatic stellate cells.\",\n      \"method\": \"Cholangiocyte-specific NIK KO, cholangiocyte-specific IKKα KO, BDL/DDC/ANIT cholestasis models, NIK inhibitor treatment, cholangiocyte proliferation/apoptosis assays, cholangiokine secretion assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic dissection of NIK vs IKKα with multiple models and mechanistic cell-type-specific readouts\",\n      \"pmids\": [\"36042192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NIK is required in dendritic cells for CD40-dependent cross-priming of CD8+ T cells; DC-specific NIK deletion impairs antigen cross-presentation to CD8+ T cells and IL-12p40 secretion by splenic CD8+ DCs, without affecting antigen presentation to CD4+ T cells.\",\n      \"method\": \"CD11c-Cre NIK conditional knockout mice, vaccination/cross-priming assays, in vitro cross-presentation assays, cytokine ELISA\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with specific cell-type functional readouts distinguishing CD8+ vs CD4+ presentation\",\n      \"pmids\": [\"26561586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DC-specific NIK activates noncanonical NF-κB to induce IL-23 expression in intestinal DCs, which maintains TH17 cells and type 3 ILCs; these produce IL-17 that drives pIgR expression on intestinal epithelial cells, enabling IgA secretion and microbiota homeostasis; DC-specific NIK deletion renders mice sensitive to Citrobacter rodentium and ameliorates colitis.\",\n      \"method\": \"DC-specific NIK knockout mice, intestinal IgA measurements, TH17/ILC3 quantification, IL-23/IL-17/pIgR expression assays, infection and colitis models\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with mechanistic pathway dissection (NIK→IL-23→IL-17→pIgR) and in vivo infection/disease models\",\n      \"pmids\": [\"30250187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NIK in lymphatic endothelial cells (LECs) regulates B-cell homing to lymph nodes by mediating expression of CXCL13 (exclusively in LECs, not blood endothelial cells) and CCL19; LEC-conditional NIK deletion severely reduces B-cell frequency in LNs without affecting LN integrity or splenic B cells.\",\n      \"method\": \"LEC-specific NIK conditional KO mice, B-cell adoptive transfer assays, chemokine ELISA/qPCR, flow cytometry of LN/spleen B-cell subsets\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with B-cell adoptive transfer establishing LEC-intrinsic NIK→CXCL13 mechanism\",\n      \"pmids\": [\"29503445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"NIK (MAP3K14) mediates cigarette smoke (CS)- and TNFα-induced histone H3K9 acetylation at pro-inflammatory gene promoters via phosphorylation of IKKα; NIK accumulates in the nuclear compartment and is recruited to promoters of pro-inflammatory genes; NIK knockdown attenuates CS/TNFα-induced histone acetylation; the canonical IKKβ/NF-κB pathway does not mediate CS-induced histone acetylation.\",\n      \"method\": \"NIK siRNA knockdown, chromatin immunoprecipitation (ChIP) for NIK and acetylated H3K9, in vivo CS exposure mouse model, immunoblot for nuclear NIK, IKKα/β phosphorylation\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — ChIP showing NIK at promoters plus siRNA knockdown; single lab with mechanistic detail\",\n      \"pmids\": [\"21887257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NEK2 phosphorylates NIK (MAP3K14), increasing NIK activity and stability, thereby activating noncanonical NF-κB signaling to promote GBM malignancy; NEK2 knockdown reduces NIK-dependent NF-κB activity and tumor progression.\",\n      \"method\": \"Co-immunoprecipitation, kinase assays showing NEK2 phosphorylates NIK, siRNA knockdown, NF-κB reporter assays, in vivo xenograft transplantation\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — kinase assay plus Co-IP identifies NEK2 as a writer for NIK; single lab\",\n      \"pmids\": [\"35031599\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MAP3K14/NIK is a constitutively active serine/threonine kinase that is kept at very low levels in resting cells through continuous proteasomal degradation mediated by a TRAF3-TRAF2-cIAP1/2 E3 ubiquitin ligase complex (which recognizes NIK via an amino-terminal IBM motif); receptor activation (LTβR, CD40, BAFF-R, EDA2R) triggers competitive displacement of NIK from TRAF3 and TRAF2-dependent K63-ubiquitination and degradation of TRAF3, stabilizing NIK to phosphorylate IKKα and drive NF-κB2/p100 processing to p52/RelB (noncanonical pathway), while also regulating canonical NF-κB, IRF3/7-dependent IFN production via STING, STAT3-dependent Th17 differentiation, JAK2/STAT3-mediated hepatocyte proliferation, RIP1-dependent apoptosis, and IKK-independent mitochondrial fission via Drp1 and actin dynamics via Arp2/3 complex phosphorylation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MAP3K14 (NF-κB-inducing kinase, NIK) is a constitutively active serine/threonine kinase that serves as the central signaling hub for the noncanonical NF-κB pathway while also regulating canonical NF-κB, interferon responses, apoptosis, mitochondrial dynamics, and metabolic homeostasis. In resting cells, NIK is continuously synthesized but rapidly degraded via a TRAF3–TRAF2–cIAP1/2 ubiquitin ligase complex that recognizes an N-terminal IAP-binding motif on NIK; receptor ligation (LTβR, CD40, BAFF-R, EDA2R) competitively displaces NIK from TRAF3 and redirects cIAP-mediated ubiquitination to degrade TRAF3, thereby stabilizing NIK to phosphorylate IKKα and drive p100-to-p52/RelB processing [PMID:18997792, PMID:20348096, PMID:25246529, PMID:16223731]. Beyond NF-κB, stabilized NIK activates STING-dependent type I interferon production, phosphorylates RIP1 to promote TNFR1-mediated apoptosis, suppresses hepatocyte proliferation through JAK2/STAT3, promotes Th17 differentiation via STAT3, and drives IKK-independent mitochondrial fission by recruiting and phosphorylating Drp1 [PMID:30018345, PMID:26045047, PMID:30070632, PMID:19411637, PMID:27889261]. Biallelic loss-of-function mutations in MAP3K14 cause a human primary immunodeficiency characterized by B-cell lymphopenia, impaired NF-κB activation, and defective NK-cell synapse formation [PMID:25406581].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Defining the physiological requirement for NIK: whereas overexpression studies had implicated NIK broadly in NF-κB signaling, knockout mice revealed a selective requirement for LTβR-dependent NF-κB activation and lymphoid organogenesis, narrowing NIK's role to specific receptor pathways.\",\n      \"evidence\": \"NIK knockout mice analyzed for NF-κB activation by multiple stimuli and lymphoid organ development\",\n      \"pmids\": [\"11251123\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of selective LTβR dependence was unknown\", \"Whether NIK had NF-κB-independent functions was not addressed\", \"Downstream substrate identity unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Establishing post-translational stabilization as the activation mechanism: pulse-chase experiments showed NIK protein is constitutively synthesized and rapidly degraded in resting B cells, and BAFF/CD40L signals stabilize NIK protein without increasing transcription, explaining how receptor signals activate NIK.\",\n      \"evidence\": \"Pulse-chase, protein synthesis inhibitor experiments in B cells stimulated with BAFF or CD40L\",\n      \"pmids\": [\"16223731\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The E3 ligase responsible for constitutive degradation was not identified\", \"Whether stabilization mechanism applied to non-B cell types was untested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of the degradation machinery: the TRAF3–TRAF2–cIAP1/2 complex was shown to constitutively ubiquitinate NIK for proteasomal destruction, and receptor engagement redirected cIAP activity to degrade TRAF3, releasing NIK; this explained both constitutive silencing and signal-induced activation of the noncanonical pathway.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, TRAF3/TRAF2-deficient cells, and mouse genetic models across multiple labs\",\n      \"pmids\": [\"18997792\", \"18292232\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TRAF3 physically contacts NIK was not mapped\", \"Whether TRAF3 loss activates canonical NF-κB through NIK needed further dissection\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Resolving the competitive displacement mechanism: mutagenesis showed that LTβR and NIK bind the same TRAF3 interface, so receptor ligation physically displaces NIK while recruiting TRAF3/TRAF2 for degradation, providing the switch logic for NIK stabilization.\",\n      \"evidence\": \"Charge-repulsion mutagenesis of TRAF3 receptor-binding site, Co-IP, LTβR signaling reconstitution\",\n      \"pmids\": [\"20348096\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometric and kinetic parameters of the switch unknown\", \"Whether all NIK-activating receptors use the same displacement mechanism was untested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Structural basis for constitutive kinase activity: the crystal structure of the NIK kinase domain revealed a constitutively active conformation stabilized by an N-terminal extension locking helix αC, explaining why NIK does not require activation-loop phosphorylation and why N-terminal truncations are gain-of-function.\",\n      \"evidence\": \"X-ray crystallography at 2.5 Å with ATPγS, kinase activity assays, and mutational analysis\",\n      \"pmids\": [\"22718757\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length NIK structure including regulatory domains unavailable\", \"How the IBM and TRAF3-binding regions interact with the kinase domain structurally unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mapping the cIAP1 recognition motif on NIK: an N-terminal IAP-binding motif (IBM) on NIK was shown to directly engage cIAP1's BIR2 domain, providing the substrate-recognition mechanism for constitutive ubiquitination; IBM mutation stabilized NIK and constitutively activated p100 processing.\",\n      \"evidence\": \"IBM mutagenesis, Co-IP with cIAP1 BIR2, ubiquitylation assays, NF-κB reporter assays\",\n      \"pmids\": [\"25246529\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether receptor signals modify the IBM-BIR2 interface is unknown\", \"Structural details of IBM-BIR2 interaction not resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Expanding NIK function beyond NF-κB: NIK-mediated phosphorylation of IKKα at Ser-176 versus Ser-180 was shown to differentially activate IRF3/7-dependent interferon production versus NF-κB, establishing NIK as a bifunctional signaling node.\",\n      \"evidence\": \"Phosphomimetic IKKα mutagenesis (S176E, S180E), IRF3/7 reporter assays, TLR stimulation\",\n      \"pmids\": [\"18068231\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for differential substrate presentation unknown\", \"In vivo validation of the dual-phosphorylation model not provided\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"NIK links adaptive immunity to T-helper cell fate: NIK-deficient T cells were selectively impaired in Th17 differentiation through defective STAT3 activation downstream of synergistic TCR and IL-6R signals, and NIK-null mice were resistant to EAE.\",\n      \"evidence\": \"NIK-/- T-cell differentiation, Rag2-/- reconstitution, STAT3 phosphorylation assays, EAE model\",\n      \"pmids\": [\"19411637\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct substrate linking NIK to STAT3 phosphorylation not identified\", \"Whether NIK acts through IKKα or independently in this context was unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Oncogenic hijacking of NIK: the API2-MALT1 fusion oncoprotein was shown to proteolytically cleave NIK at Arg325, generating a degradation-resistant C-terminal kinase fragment that drives constitutive noncanonical NF-κB, linking NIK stabilization to MALT lymphoma pathogenesis.\",\n      \"evidence\": \"Biochemical cleavage assays, Arg325 mutagenesis, NF-κB reporter and adhesion/apoptosis assays\",\n      \"pmids\": [\"21273489\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether therapeutic targeting of the cleavage product is feasible unknown\", \"Frequency and contribution of this mechanism across MALT lymphoma subtypes unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"NIK in bone biology: NIK stabilization in osteoclast precursors accelerated osteoclastogenesis and bone resorption via constitutive alternative NF-κB, while NIK deficiency blocked osteoclast differentiation through cytoplasmic p100 retention, establishing NIK as a critical regulator of bone homeostasis.\",\n      \"evidence\": \"Transgenic gain-of-function (TRAF3-binding-deficient NIK), NIK-/- osteoclast cultures, bone resorption assays, arthritis models\",\n      \"pmids\": [\"21151480\", \"18322009\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"NIK's role in osteoblasts not examined\", \"Whether therapeutic NIK inhibition could treat osteoporosis without immunosuppression unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Metabolic function of NIK: hepatic NIK was shown to promote glucagon-stimulated glucose production by stabilizing CREB; NIK was abnormally activated in obese mouse livers, linking NIK to metabolic disease.\",\n      \"evidence\": \"Liver-specific NIK KO, hepatocyte-specific transgene, primary hepatocyte glucose production, CREB stability assays\",\n      \"pmids\": [\"22581287\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How NIK stabilizes CREB mechanistically (direct phosphorylation vs indirect) not resolved\", \"Human relevance of hepatic NIK elevation in obesity not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Human disease causation: biallelic loss-of-function MAP3K14 mutations were identified as a cause of primary immunodeficiency, with abolished kinase activity leading to defective NF-κB activation, B-cell lymphopenia, and impaired NK-cell function, confirming the mouse knockout phenotype in humans.\",\n      \"evidence\": \"Patient genetics, in vitro kinase assays, lymphocyte subset flow cytometry, NK synapse imaging\",\n      \"pmids\": [\"25406581\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype-phenotype spectrum in additional patients not established\", \"Whether partial loss-of-function alleles cause milder phenotypes unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"NF-κB-independent apoptotic function: NIK was shown to directly phosphorylate RIP1 and promote RIP1/FADD/caspase-8 complex assembly for TNFR1-mediated apoptosis, a function independent of p100 processing, revealing that NIK integrates cell death and survival signals.\",\n      \"evidence\": \"In vitro kinase assay (NIK phosphorylating RIP1), NIK-/- and p100-/- mice, in vivo thymus/liver damage models\",\n      \"pmids\": [\"26045047\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RIP1 phosphorylation site(s) not identified\", \"How cells balance NIK's pro-survival NF-κB and pro-death RIP1 functions unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"NF-κB-independent mitochondrial function: NIK was found to localize to mitochondria and promote fission by recruiting and regulating Drp1 phosphorylation (Ser-616/Ser-637), independently of IKKα/β, linking NIK to organelle dynamics and cell migration.\",\n      \"evidence\": \"Subcellular fractionation, live-cell imaging, Co-IP of NIK-Drp1, IKK-null MEFs, invasion assays\",\n      \"pmids\": [\"27889261\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How NIK is targeted to mitochondria unknown\", \"Whether mitochondrial NIK pool is regulated by the TRAF3 degradation machinery unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Innate DNA sensing: NIK was shown to interact with STING independently of alternative NF-κB components; NIK autophosphorylation and oligomerization activate STING-dependent IFN, and NIK-deficient mice are more susceptible to DNA viruses, establishing NIK as a node linking innate DNA sensing to interferon production.\",\n      \"evidence\": \"Reciprocal Co-IP of NIK-STING, autophosphorylation/oligomerization assays, IFN reporters, in vivo DNA virus infection\",\n      \"pmids\": [\"30018345\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NIK directly phosphorylates STING or another intermediate unknown\", \"Relationship between NIK-STING and NIK-IKKα-IRF3 pathways not clarified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Hepatocyte proliferation control: conditional deletion of NIK or IKKα in hepatocytes accelerated liver regeneration after partial hepatectomy by derepressing JAK2/STAT3, positioning NIK-IKKα as a brake on hepatocyte proliferation.\",\n      \"evidence\": \"Hepatocyte-specific Map3k14 and Chuk KO mice, partial hepatectomy, JAK2/STAT3 phosphorylation, disease models\",\n      \"pmids\": [\"30070632\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which NIK-IKKα suppresses JAK2/STAT3 not identified\", \"Whether this pathway operates in non-hepatocyte epithelial cells untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Cell-type-specific immune roles: DC-specific NIK was shown to drive IL-23 production for intestinal Th17/ILC3 maintenance and IgA homeostasis, while LEC-specific NIK controlled CXCL13-dependent B-cell homing to lymph nodes, demonstrating that NIK acts through distinct effector programs in different stromal and immune cell types.\",\n      \"evidence\": \"DC-specific and LEC-specific NIK conditional KO mice, infection/colitis models, B-cell adoptive transfer, chemokine assays\",\n      \"pmids\": [\"30250187\", \"29503445\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NIK-dependent transcriptional programs differ across DC subsets not fully resolved\", \"Upstream receptor activating NIK in LECs not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"IKKα-independent biliary function: cholangiocyte-specific NIK deletion (but not IKKα deletion) blunted ductular reaction, fibrosis, and inflammation during cholestasis, demonstrating an IKKα-independent NIK effector pathway in biliary epithelial cells.\",\n      \"evidence\": \"Cholangiocyte-specific NIK KO vs IKKα KO, BDL/DDC/ANIT cholestasis models, proliferation/apoptosis/cholangiokine assays\",\n      \"pmids\": [\"36042192\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The IKKα-independent substrate mediating ductular reaction not identified\", \"Whether this pathway contributes to cholangiocarcinoma unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Muscle atrophy via EDA2R-NIK axis: EDA-A2/EDA2R signaling was shown to activate NIK-dependent noncanonical NF-κB in skeletal muscle, upregulating atrophy genes; muscle-specific NIK deletion protected against cancer cachexia, identifying a new receptor-kinase axis in muscle wasting.\",\n      \"evidence\": \"Primary myotube assays, muscle-specific NIK KO, EDA2R KO, tumor-bearing cachexia models, NIK inhibitor treatment\",\n      \"pmids\": [\"37165186\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NIK inhibitors can treat cachexia without immunosuppression unknown\", \"Direct NIK substrates in skeletal muscle not characterized\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major unresolved questions include the full-length structure of NIK with its regulatory domains, the mechanism by which NIK is targeted to mitochondria, the identity of IKKα-independent substrates in cholangiocytes, and how cells integrate NIK's pro-survival (NF-κB), pro-death (RIP1), and metabolic (CREB, JAK2/STAT3) outputs.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Full-length NIK structure unavailable\", \"Mitochondrial targeting mechanism unknown\", \"IKKα-independent downstream effectors in non-immune cells unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [2, 7, 8, 16, 20, 31]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [30]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 4, 5, 6, 10, 14, 16, 25]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 11, 13, 14, 27, 28, 29]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [20]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 11, 24]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [12]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"complexes\": [\n      \"TRAF3-TRAF2-cIAP1/2 degradation complex (substrate)\"\n    ],\n    \"partners\": [\n      \"TRAF3\",\n      \"TRAF2\",\n      \"BIRC2\",\n      \"CHUK\",\n      \"STING1\",\n      \"DNM1L\",\n      \"RIPK1\",\n      \"NEK2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}